Merck To Present New Data Across Its HIV Treatment And Prevention Pipeline And Portfolio At HIV Drug Therapy Glasgow 2026
Key takeaways
- Merck’s upcoming Glasgow presentation will test the real‑world effectiveness of its new once‑weekly and once‑monthly oral HIV drugs.
What happened
Merck will show new data on its HIV treatment and prevention drugs at the HIV Drug Therapy Glasgow 2026 conference, including Phase 3 subgroup results and patient‑reported outcomes for its once‑weekly oral combination of islatravir/lenacapavir (ISL/LEN) and other investigational regimens.
Why it matters
The data will inform how Merck’s expanding oral HIV options perform in real‑world settings, potentially shaping future treatment guidelines and market share for its portfolio.
Short-term and longer-term
Short-term. Merck’s presentation could lead to short‑term price swings if the data show strong efficacy or safety signals.
Longer-term. Over the next few months, the results could reshape Merck’s HIV portfolio strategy, impacting long‑term revenue streams and competitive dynamics in the oral HIV market.
Words on this card
- PrEP
- Pre‑exposure prophylaxis, a medication taken by HIV‑negative people to reduce the risk of infection
- Phase 3
- The final stage of clinical trials before a drug can be approved for use
- Patient‑reported outcomes
- Information collected directly from patients about their health status and treatment experience